Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
BRISBANE, Calif., May 03, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it will host a company overview webinar on Wednesday, May 10, 2017, at 1:30 p.m. ET.
Dr. Cameron Durrant, chairman and CEO, will present an update on the company, its growth initiative progress and upcoming key milestones. The webinar will feature a presentation that can be accessed via the webcast link below. A question-and-answer session will follow.
Date: Wednesday, May 10, 2017
Time: 1:30 p.m. ET (10:30 a.m. PT)
Dial-in: 1-888-267-6301
Toll/International Dial-in: 1-719-457-2734
Webcast: http://public.viavid.com/index.php?id=124313
A telephone replay will be available approximately two hours after the call through June 10, 2017. Access the replay by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from international locations, and entering the replay pin number: 8563194.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab, for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
